* Newstin.com is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.com and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.com is for sale! *

XenoPort

                   

Analyst Comments: XenoPort, Standard Motor, Vital Images, Ingram Micro, Bank of Ireland, Napster

istockanalyst.com
Sep 19, 2008
        

XenoPort, Inc.?s (XNPT) lead candidate is Solzira (XP-13512), a Transported Prodrug of gabapentin. XenoPort is partnered with GlaxoSmithKline (GSK) for development and commercialization in the U.S. and select countries...

add comment

GlaxoSmithKline and XenoPort File NDA for Restless Legs Syndrome Drug

redorbit.com
Sep 17, 2008 5 related
        

GlaxoSmithKline and XenoPort have announced that a new drug application has been submitted to the FDA requesting approval of Solzira extended release tablets for the treatment of moderate-to-severe primary restless legs...

add comment

Glaxo submits restless leg drug for FDA approval

ibtimes.com
Sep 16, 2008 2 related
        

WASHINGTON - GlaxoSmithKline said Tuesday it has asked U.S. health regulators to approve an experimental drug for restless leg syndrome which it developed with partner Xenoport. The companies have touted Solzira as the...

add comment

XenoPort to Present at the Morgan Stanley Healthcare Conference

finanznachrichten.de
Sep 3, 2008 1 related
        

XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Morgan Stanley Global Healthcare Unplugged Conference. The live presentation will occur at 8:30...

add comment

DIARY - U.S Meetings for Week Ahead - Part 1 =2

finanznachrichten.de
Sep 3, 2008
        

Sept 3 (Reuters) - *** TO SEE THE DATES BEFORE Sep 09 - PLEASE CLICK ON [US/MEETM] DATE GMT SYMBOL EVENT TITLE 09 Sep 12:00 SCMP.O Sucampo Pharma.s, Inc at Morgan Stanley Global Conf 09 Sep 17:20 SFSF.O SUCCESSFACTORS...

add comment

Xanodyne Pharmaceuticals, Inc. Achieves Positive Efficacy Results in Pivotal Phase 3 Studies of...

pharmiweb.co.uk
Aug 12, 2008
        

menstrual bleeding, and its accompanying symptoms. "We are extremely pleased with the initial data from these pivotal trials and we look forward to continuing to work with the U.S. Food and Drug Administration (FDA) to complete...

add comment
                   

Earnings roundup: Swift Energy, XenoPort

ibtimes.com
Aug 7, 2008 4 related
        

Among the earnings stories for Thursday, Aug. 7, from AP Financial News: HOUSTON (AP)--Oil and natural-gas producer Swift Energy Co. said Thursday its second-quarter profit more than doubled on high commodity prices and strong...

add comment
                   

XenoPort Reports Second Quarter Financial Results (Business Wire)

yahoo.com
Aug 7, 2008
        

SANTA CLARA, Calif.----XenoPort, Inc. announced today financial results for the second quarter and six months ended June 30, 2008. Revenues for the second quarter were $11.5 million, compared to $36.1 million for the same...

add comment
genengnews.com: Genetic Engineering genengnews.com

XenoPort Appoints Per G. H. Lofberg to Board (Business Wire)

yahoo.com
Jul 31, 2008 2 related
        

Thursday July 31, 8:30 am ET SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq:XNPT - News ) announced today the appointment of Per G. H. Lofberg to its board of directors. Mr. Lofberg is currently Chairman and a...

add comment
genengnews.com: Genetic Engineering genengnews.com

XenoPort to Release Second Quarter Financial Results on August 6, 2008

redorbit.com
Jul 17, 2008 9 related
        

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its second quarter financial results on August 6, 2008, at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern...

add comment
1 2 3 4 5 next »